Dalbavancin: A novel once-weekly lipoglycopeptide antibiotic

Clinical Infectious Diseases

Volumn 46, Issue 4, 2008, Pages 577-583

  Billeter, Marianne ^a   Zervos, Marcus J ^b,c   Chen, Anne Y ^b,c   Dalovisio, Joseph R ^a   Kurukularatne, Changa ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFTRIAXONE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; LINEZOLID; METICILLIN; PENICILLIN G; PROCAINE PENICILLIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG DERIVATIVE;

BACTERIAL PNEUMONIA; CATHETER INFECTION; DRUG EFFICACY; DRUG HALF LIFE; ENDOCARDITIS; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; UNSPECIFIED SIDE EFFECT; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; HALF LIFE TIME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TEICOPLANIN;

EID: 38849104549     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/526772     Document Type: Review

References (43)

1. Moran JG, Krishnadsan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
2. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:1079-82.
3. Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC Jr, Eliopoulos GM. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 2007; 51:2223-5.
4. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581-5.
5. Lin SW, Carver PL, DePestel DD. Dalbavancin: a new option for the treatment of gram-positive infections. Ann Pharmacother 2006; 40:449-60.
6. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005; 55(Suppl S2):ii15-20.
7. Streit JM, Fritsche TR, Sader H, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48:137-43.
8. Malabarba A, Ciabatti R. Glycopeptide derivatives. Curr Med Chem 2001; 8:1759-73.
9. Pope SD, Roecker AM. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 2006; 26:908-18.
10. Streit JM, Sader HS, Fritsche T, Jones RN. Dalbavancin activity against selected populations of antimicrobial-resistant gram-positive pathogens. Diagn Microbiol Infect Dis 2005; 53:307-10.
11. Jones RN, Sader HS, Fritsche TR. Dalbavancin (DAL; formerly BI397) activity against selected populations of antimicrobial-resistant gram-positive pathogens [abstract 172]. In: Program and abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (San Diego). Arlington, VA: Infectious Diseases Society of America, 2003:172.
12. Flamm RK, Draghi DC, Karlowsky JA, Sahm DF. Activity of dalbavancin against clinical isolates of staphylococci and streptococci from U.S. and Europe [abstract E-2008]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
13. Jones RN, Sader HS, Fritsche TR, Stilwell M. Comparative activity of dalbavancin tested against 7,771 isolates from the USA and Europe [abstract E-2009]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
14. Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 2005; 11:95-100.
15. Jones RN, Biedenbach DJ, Johnson DM, Pfaller MA. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J Chemother 2001; 13:244-54.
16. Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999; 44:179-92.
17. Appelbaum PC, Kelly LM, Ednie LM, Smith K, Jacobs MR, Bozdogan B. Comparative activities of dalbavancin (DAL) against staphylococci, including a vancomycin-resistant strain of Staphylococcus aureus [abstract 173]. In: Program and abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (San Diego). Arlington, VA: Infectious Diseases Society of America, 2003.
18. Hackbarth CJ, Lopez S, Trias J, White R. In vitro activity of the glycopeptide BI 397 against Staphylococcus aureus and Staphylococcus epidermidis [abstract 1283]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999.
19. Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007; 51:1150-4.
20. Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005; 49:770-2.
21. Lin G, Smith K, Ednie LM, Appelbaum PC. Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob Agents Chemother 2005; 49:5182-4.
22. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT. In-vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother 2003; 47:1968-71.
23. Mushtaq S, Warner M, Johnson A, Livermore DM. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods. J Antimicrob Chemother 2004; 54:617-20.
24. Cavaleri M, Simona R, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005; 55(Suppl S2):ii31-5.
25. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:940-5.
26. Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005; 45:1279-87.
27. Dowell JA, Gottlieb AB, van Saders C, et al. The pharmacokinetics and renal excretion of dalbavancin in healthy subjects [abstract A-1386]. In: Abstracts and Final Program of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
28. Dowell J, Seltzer E, Stogniew M, et al. Dalvavancin (DAL) pharmacokinetcs (PK) in subjects with mild or moderate hepatic impairment (HI) [abstract A-19]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003.
29. Dowell JA, Seltzer E, Buckwalter M, Marbury T. The pharmacokinetics of dalbavancin (DAL) in subjects with mild, moderate or severe hepatic impairment (HI) [A-19]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
30. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007; 51:1633-42.
31. Jabes D, Candiani G, Romano G, Brunati C, Riva S, Cavaleri M. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 2004; 48:1118-23.
32. Candiani GP, Romano G, Cavaleri M, et al. Efficacy of a single dalbavancin (DA) dose compared with multiple linezolid (LN) doses against penicillin-resistant pneumococci (PRSP) in a lobar pneumonia (LP) model in the immunocompetent rat (IR) [abstract B-989]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
33. Darouiche RO, Mansouri MD. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J Infect 2005; 50:206-9.
34. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40:374-80.
35. Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and softtissue infections. Clin Infect Dis 2003; 37:1298-303.
36. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of a once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407-15.
37. Goldstein BP, Seltzer E, Flamm R, Sahm D. Dalbavancin phase 3 skin and skin structure studies: pathogens and microbiological efficacy [abstract L-1577]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005.
38. Seltzer E, Goldberg L, Krause D. Safety of dalbavancin (DAL) in a clinical development program [abstract L-1576]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005.
39. Nord C, Rasmanis G, Wahlund E. Effect of dalbavancin on normal intestinal microflora [A-13]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005.
40. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 2007; 27:227-49.
41. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
42. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42:597-607.
43. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004; 188:760-6.